|
|
|
|
|
||
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online 1 February 2005
doi: 10.1242/jcs.01653
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Article |
Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center, 79106 Freiburg, Germany
* Author for correspondence (e-mail: augustin{at}angiogenese.de)
Accepted 17 November 2004
The angiopoietins Ang-1 and Ang-2 have been identified as ligands of the endothelial receptor tyrosine kinase Tie-2, which controls vascular assembly and endothelial quiescence. The largely complementary phenotypes of Ang-1-deficient mice and Ang-2-overexpressing mice have led to an antagonistic model in which Ang-1 acts as Tie-2-activating agonist and Ang-2 acts as a Tie-2-inhibiting antagonist. To date, no mechanistic equivalent of the antagonistic Ang-1/Ang-2 model has been established and the mechanisms of Ang-2 function in particular remain mysterious. We have studied the effector functions of Ang-1 and Ang-2 on quiescent endothelial cells using a three-dimensional co-culture model of endothelial cells and smooth-muscle cells. Endothelial-cell monolayer integrity in this model is dependent on Tie-2 signaling, as evidenced by detaching endothelial cells following exposure to the small molecular weight Tie-2 inhibitor A-422885.66, which cannot be overcome by exogenous Ang-1. Accordingly, exogenous Ang-2 rapidly destabilizes the endothelial layer, which can be observed within 30-60 minutes and leads to prominent endothelial-cell detachment within 4 hours. Exogenous Ang-2-mediated endothelial-cell detachment can be rescued by Ang-1, soluble Tie-2 and vascular endothelial growth factor. Similar findings were obtained in an umbilical-vein explant model. Ang-2 is mainly produced by endothelial cells and therefore acts primarily in an autocrine manner. Thus, stimulated release of endogenous Ang-2 or overexpression of Ang-2 in endothelial cells perturbs co-culture spheroid integrity, which can be rescued by exogenous Ang-1 and vascular endothelial growth factor. However, autocrine Ang-2-mediated endothelial-cell detachment cannot be blocked by soluble Tie-2. Taken together, the data demonstrate for the first time the antagonistic Ang-1/Ang-2 concept in a defined cellular model and identify Ang-2 as a rapidly acting autocrine regulator of the endothelium that acts through an internal autocrine loop mechanism.
Key words: Angiopoietin, Endothelial cells, Angiogenesis
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  P Kumpers, S David, M Haubitz, J Hellpap, R Horn, V Brocker, M Schiffer, H Haller, and T Witte The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus Ann Rheum Dis, October 1, 2009; 68(10): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Figueroa-Vega, M. Alfonso-Perez, C. Cuesta-Mateos, F. Sanchez-Madrid, R. Moreno-Otero, R. Gonzalez-Amaro, and M. Marazuela Tie-2 Is Overexpressed by Monocytes in Autoimmune Thyroid Disorders and Participates in Their Recruitment to the Thyroid Gland J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2626 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmed, T. Fujisawa, X.-L. Niu, S. Ahmad, B. Al-Ani, K. Chudasama, A. Abbas, R. Potluri, V. Bhandari, C. M. Findley, et al. Angiopoietin-2 Confers Atheroprotection in apoE-/- Mice by Inhibiting LDL Oxidation via Nitric Oxide Circ. Res., June 19, 2009; 104(12): 1333 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kumpers, J. Hellpap, S. David, R. Horn, H. Leitolf, H. Haller, and M. Haubitz Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1845 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Jin and C. Patterson The Opening Act: Vasculogenesis and the Origins of Circulation Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Yuan, E. V. Khankin, S. A. Karumanchi, and S. M. Parikh Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium Mol. Cell. Biol., April 15, 2009; 29(8): 2011 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Figueroa-Vega, P. Sanz-Cameno, R. Moreno-Otero, F. Sanchez-Madrid, R. Gonzalez-Amaro, and M. Marazuela Serum Levels of Angiogenic Molecules in Autoimmune Thyroid Diseases and Their Correlation with Laboratory and Clinical Features J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jang, Y. J. Koh, N. K. Lim, H. J. Kang, D. H. Kim, S. K. Park, G. M. Lee, C. J. Jeon, and G. Y. Koh Angiopoietin-2 Exocytosis Is Stimulated by Sphingosine-1-Phosphate in Human Blood and Lymphatic Endothelial Cells Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 401 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nasarre, M. Thomas, K. Kruse, I. Helfrich, V. Wolter, C. Deppermann, D. Schadendorf, G. Thurston, U. Fiedler, and H. G. Augustin Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth Cancer Res., February 15, 2009; 69(4): 1324 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Helfrich, L. Edler, A. Sucker, M. Thomas, S. Christian, D. Schadendorf, and H. G. Augustin Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma Clin. Cancer Res., February 15, 2009; 15(4): 1384 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Abramovich, A. R. Celin, F. Hernandez, M. Tesone, and F. Parborell Spatiotemporal analysis of the protein expression of angiogenic factors and their related receptors during folliculogenesis in rats with and without hormonal treatment Reproduction, February 1, 2009; 137(2): 309 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kohno, T. Daa, H. Otani, I. Shimokawa, S. Yokoyama, and T. Matsuyama Aberrant expression of BAFF receptor, a member of the tumor necrosis factor receptor family, in malignant cells of nonhematopoietic origins Genes Cells, October 1, 2008; 13(10): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M van der Heijden, G P van Nieuw Amerongen, P Koolwijk, V W M van Hinsbergh, and A B J Groeneveld Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients Thorax, October 1, 2008; 63(10): 903 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kumpers, C. Koenecke, H. Hecker, J. Hellpap, R. Horn, W. Verhagen, S. Buchholz, B. Hertenstein, J. Krauter, M. Eder, et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Blood, September 1, 2008; 112(5): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anargyrou, E. Terpos, T. P. Vassilakopoulos, A. Pouli, S. Sachanas, T. Tzenou, S. Masouridis, D. Christoulas, M. K. Angelopoulou, E. M. Dimitriadou, et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib Haematologica, March 1, 2008; 93(3): 451 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lan, B. Liu, H. Yao, F. Li, T. Weng, G. Yang, W. Li, X. Cheng, N. Mao, and X. Yang Essential Role of Endothelial Smad4 in Vascular Remodeling and Integrity Mol. Cell. Biol., November 1, 2007; 27(21): 7683 - 7692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Liu, J. Wang, B. Kinzel, M. Mueller, X. Mao, R. Valdez, Y. Liu, and E. Li Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity Blood, September 1, 2007; 110(5): 1502 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. de Caestecker Angiopoietin-2 and Glomerular Proteinuria J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2217 - 2218. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dome, M. J.C. Hendrix, S. Paku, J. Tovari, and J. Timar Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications Am. J. Pathol., January 1, 2007; 170(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Daly, E. Pasnikowski, E. Burova, V. Wong, T. H. Aldrich, J. Griffiths, E. Ioffe, T. J. Daly, J. P. Fandl, N. Papadopoulos, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells PNAS, October 17, 2006; 103(42): 15491 - 15496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pfaff, U. Fiedler, and H. G. Augustin Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking J. Leukoc. Biol., October 1, 2006; 80(4): 719 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kalomenidis, A. Kollintza, I. Sigala, A. Papapetropoulos, S. Papiris, R. W. Light, and C. Roussos Angiopoietin-2 Levels Are Elevated in Exudative Pleural Effusions Chest, May 1, 2006; 129(5): 1259 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P.J. Brindle, P. Saharinen, and K. Alitalo Signaling and Functions of Angiopoietin-1 in Vascular Protection Circ. Res., April 28, 2006; 98(8): 1014 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Phelps, D. L. Updike, E. C. Bullen, P. Grammas, and E. W. Howard Transcriptional and posttranscriptional regulation of angiopoietin-2 expression mediated by IGF and PDGF in vascular smooth muscle cells Am J Physiol Cell Physiol, February 1, 2006; 290(2): C352 - C361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Fathers, C. M. Stone, K. Minhas, J. J.A. Marriott, J. D. Greenwood, D. J. Dumont, and B. L. Coomber Heterogeneity of Tie2 Expression in Tumor Microcirculation: Influence of Cancer Type, Implantation Site, and Response to Therapy Am. J. Pathol., December 1, 2005; 167(6): 1753 - 1762. [Abstract] [Full Text] [PDF]
|
|
